112734-21-1

Basic information

• Product Name: Benzoyl chloride, 4-bromo-2-nitro-
• CAS NO: 112734-21-1
• Molecular Formula: C7H3BrClNO3
• Molecular Weight: 264.463
• Mol File: 112734-21-1.mol

Chemical Properties

• CAS DataBase Reference: Benzoyl chloride, 4-bromo-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 4-bromo-2-nitro-(112734-21-1)
• EPA Substance Registry System: Benzoyl chloride, 4-bromo-2-nitro-(112734-21-1)

Safety Data

• Hazardous Substances Data: 112734-21-1(Hazardous Substances Data)

Upstream product

• 99277-71-1 4-bromo-2-nitrobenzoic acid 
• 4727-72-4 1-benzyl-4-hydroxypiperidine 

Downstream Products

• 171819-63-9 Methyl 4-bromo-β-tert-butyl-2-nitrohippurate 
• 890315-72-7 tert-butyl 4-bromo-2-nitrobenzoate 

Relevant articles and documents

Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands

A novel strategy for the synthesis of cholecystokinin-2 receptor ligands was developed. The route employs a solution-phase synthesis of a series of anthranilic sulfonamides followed by a resin capture purification strategy to produce multi-milligram quant

A stereoselective approach to peptidomimetic BACE1 inhibitors

Aiming at identifying new scaffolds to generate beta-secretase (BACE1) inhibitors we developed peptidomimetics based on a 1,4-benzodiazepine core (3a-d), their seco-analogs (4a-b), and linear analogs (5a-h), by stereoselective approaches. We herein discuss the synthesis, molecular modeling and in vitro studies for the newly developed ligands. Compounds 5c and 5h behaved as BACE1 inhibitors on the isolated enzyme and in cellular studies. Particularly, for its low molecular weight, inhibitor 5h is a prototypic hit to develop a series of BACE1 inhibitors more potent and active on whole-cells.

Scaffold and Parasite Hopping: Discovery of New Protozoal Proliferation Inhibitors

Utilizing a target repurposing and parasite-hopping approach, we tested a previously reported library of compounds that were active against Trypanosoma brucei, plus 31 new compounds, against a variety of protozoan parasites including Trypanosoma cruzi, Leishmania major, Leishmania donovani, and Plasmodium falciparum. This led to the discovery of several compounds with submicromolar activities and improved physicochemical properties that are early leads toward the development of chemotherapeutic agents against kinetoplastid diseases and malaria.

PRMT5 INHIBITORS

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

Indole compounds as well as preparation method, pharmaceutical composition and application thereof

The invention discloses indole compounds with structural characteristics of a formula (I), metabolites, metabolic precursors, prodrugs, solvates, crystals or pharmaceutically acceptable salts thereof,a preparation method of the indole compounds, and an application of the indole compounds and the metabolites, the metabolic precursors, the prodrugs, the solvates, the crystals or the pharmaceutically acceptable salts thereof as an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. Experimental results show that the compound disclosed by the invention has a remarkable inhibition effect on the activity of IDO1; T lymphocyte proliferation can be effectively promoted; the initial T lymphocytes are inhibited from being differentiated into regulatory T cells; the IDO1-mediated immunosuppressive effect is reversed, and the compounds can be used for treating related diseases, including cancers, viral infections, neurodegenerative diseases, cataract, organ transplant rejection, depression, autoimmune diseases and the like, with pathological characteristics of an IDO1-mediated kynurenine metabolic pathway.

Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development

Lapatinib, an approved epidermal growth factor receptor inhibitor, was explored as a starting point for the synthesis of new hits against Trypanosoma brucei, the causative agent of human African trypanosomiasis (HAT). Previous work culminated in 1 (NEU-1953), which was part of a series typically associated with poor aqueous solubility. In this report, we present various medicinal chemistry strategies that were used to increase the aqueous solubility and improve the physicochemical profile without sacrificing antitrypanosomal potency. To rank trypanocidal hits, a new assay (summarized in a cytocidal effective concentration (CEC50)) was established, as part of the lead selection process. Increasing the sp3 carbon content of 1 resulted in 10e (0.19 μM EC50 against T. brucei and 990 μM aqueous solubility). Further chemical exploration of 10e yielded 22a, a trypanocidal quinolinimine (EC50: 0.013 μM; aqueous solubility: 880 μM; and CEC50: 0.18 μM). Compound 22a reduced parasitemia 109 fold in trypanosome-infected mice; it is an advanced lead for HAT drug development.

2-Aminoquinazolin-4(3H)-one based plasmepsin inhibitors with improved hydrophilicity and selectivity

2-Aminoquinazolin-4(3H)-ones were previously discovered as perspective leads for antimalarial drug development targeting the plasmepsins. Here we report the lead optimization studies with the aim to reduce inhibitor lipophilicity and increase selectivity

PYRAZOLOQUINOLINE DERIVATIVES

A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.

INHIBITORS OF LRRK2 KINASE ACTIVITY

The present invention provides compounds having a structure according to Formula I: (I) or a salt or solvate thereof, wherein R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

Small Molecule Inhibitors of Toll-Like Receptor 9

Small molecule compounds and compositions containing said compounds useful for inhibiting signaling by certain Toll-like receptors (TLRs), particularly TLR9, are provided. The compounds and compositions can be used to inhibit immune responses, including unwanted immune responses in particular. Compounds, compositions, and methods are provided to treat a variety of conditions involving unwanted immune responses, including for example autoimmune disease, inflammation, transplant rejection, and sepsis.